Biomarkers of alopecia areata disease activity and response to corticosteroid treatment

Alopecia areata (AA) is a common inflammatory disease targeting the anagen‐stage hair follicle. Different cytokines have been implicated in the disease profile, but their pathogenic role is not yet fully determined. We studied biopsies of pretreatment lesional and non‐lesional (NL) scalp and post‐treatment (intra‐lesional steroid injection) lesional scalp of 6 patchy patients with AA using immunohistochemistry and gene expression analysis. Immunohistochemistry showed increases in CD3+, CD8+ T cells, CD11c+ dendritic cells and CD1a+ Langerhans cells within and around hair follicles of pretreatment lesional scalp, which decreased upon treatment. qRT‐PCR showed in pretreatment lesional scalp (compared to NL) significant increases (P < 0.05) in expression of inflammatory markers (IL‐2, IL‐2RA, JAK3, IL‐15), Th1 (CXCL10 and CXCL9), Th2 (IL‐13, CCL17 and CCL18), IL‐12/IL‐23p40 and IL‐32. Among these, we observed significant downregulation with treatment in IL‐12/IL‐23p40, CCL18 and IL‐32. We also observed significant downregulation of several hair keratins in lesional scalp, with significant upregulation of KRT35, KRT75 and KRT86 in post‐treatment lesional scalp. This study shows concurrent activation of Th1 and Th2 immune axes as well as IL‐23 and IL‐32 cytokine pathways in lesional AA scalp and defined a series of response biomarkers to corticosteroid injection. Clinical trials with selective antagonists coupled with cytokine‐pathway biomarkers will be necessary to further dissect pathogenic immunity.

[1]  M. Lebwohl,et al.  Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. , 2015, The Journal of allergy and clinical immunology.

[2]  A. Christiano,et al.  Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib , 2015, EBioMedicine.

[3]  N. Sheikh,et al.  A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation , 2015, European Journal of Medical Research.

[4]  A. Christiano,et al.  Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition , 2014, Nature Medicine.

[5]  W. Sterry,et al.  IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization , 2014, Cancer Immunology Research.

[6]  M. Suárez-Fariñas,et al.  Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights , 2014, The Journal of investigative dermatology.

[7]  A. Schrum,et al.  Lifetime incidence risk of Alopecia Areata estimated at 2.1 percent by Rochester Epidemiology Project, 1990–2009 , 2013, The Journal of investigative dermatology.

[8]  G. Kalkan,et al.  The association between Interleukin (IL)-4 gene intron 3 VNTR polymorphism and alopecia areata (AA) in Turkish population. , 2013, Gene.

[9]  S. Choi,et al.  Combination Therapy with Cyclosporine and Psoralen Plus Ultraviolet A in the Patients with Severe Alopecia Areata: A Retrospective Study with a Self-Controlled Design , 2013, Annals of dermatology.

[10]  A. Christiano,et al.  Genetic basis of alopecia areata: a roadmap for translational research. , 2013, Dermatologic clinics.

[11]  M. Nöthen,et al.  Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. , 2012, The Journal of investigative dermatology.

[12]  Lisa C. Zaba,et al.  A subpopulation of CD163-positive macrophages is classically activated in psoriasis. , 2010, The Journal of investigative dermatology.

[13]  A. Sinha,et al.  Transcriptional profiling in alopecia areata defines immune and cell cycle control related genes within disease-specific signatures. , 2010, Genomics.

[14]  C. Akdis,et al.  IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. , 2010, The Journal of allergy and clinical immunology.

[15]  J. Redzic,et al.  Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. , 2008, The Journal of investigative dermatology.

[16]  Kyoung-Chan Park,et al.  Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata , 2008, The Journal of dermatological treatment.

[17]  H. Winter,et al.  Hair follicle-specific keratins and their diseases. , 2007, Experimental cell research.

[18]  Kathleen M. Smith,et al.  IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis , 2006, The Journal of experimental medicine.

[19]  Masaaki Ito,et al.  Human hair keratin-associated proteins. , 2005, The journal of investigative dermatology. Symposium proceedings.

[20]  R. Happle,et al.  Alopecia areata: treatment of today and tomorrow. , 2003, The journal of investigative dermatology. Symposium proceedings.

[21]  J. Sundberg,et al.  Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. , 2002, The Journal of investigative dermatology.

[22]  L Langbein,et al.  The Catalog of Human Hair Keratins , 1999, The Journal of Biological Chemistry.

[23]  H. Winter,et al.  Sequences and differential expression of three novel human type-II hair keratins. , 1997, Differentiation; research in biological diversity.

[24]  J. Messina,et al.  Cutaneous T-cell Lymphoma. , 1998, Cancer control : journal of the Moffitt Cancer Center.